Skip to main content
Premium Trial:

Request an Annual Quote

Why Choose Just One?

The UK is planning a clinical trial for next year to test whether giving people doses of different SARS-CoV-2 vaccines will provide better protection than two doses of the same vaccine, according to the Guardian.

The trial, it says, is to begin in January if the vaccine from AstraZeneca and Oxford University gains authorization. Participants would receive one dose of that vaccine and one dose of the Pfizer/BioNTech vaccine, which already has authorization in the UK. The Guardian adds that if the SARS-CoV-2 vaccine from Moderna receives authorization, it too will be included in the trial.

Kate Bingham, outgoing chair of the UK's vaccine taskforce, says the concept is known as a heterologous prime-boost. "It means mix and matching vaccines," she says.

The Guardian adds that "the idea is to combine them, in whichever order, to help the immune system respond more powerfully to SARS-CoV-2."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.